Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled, dose-ranging study of CDP6038 (olokizumab) in rheumatoid arthritis
2010-020839-39Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (3 arms), sponsored by UCB. Primary endpoint: Primary efficacy variables. Started Oct 2010; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-020839-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020839-39.